In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014–2018 studies in Italy
ABSTRACT: Objectives: : Antimicrobial resistance, particularly carbapenem resistance, in Gram-negative pathogens poses a significant healthcare threat. Carbapenem resistance rates in Italy are among the highest in Europe. We report the in vitro activity of cefiderocol, a novel siderophore cephalosp...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-06-01
|
| Series: | Journal of Global Antimicrobial Resistance |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213716521001181 |
| _version_ | 1819098181129994240 |
|---|---|
| author | Stefano Stracquadanio Eleonora Torti Christopher Longshaw Anne Santerre Henriksen Stefania Stefani |
| author_facet | Stefano Stracquadanio Eleonora Torti Christopher Longshaw Anne Santerre Henriksen Stefania Stefani |
| author_sort | Stefano Stracquadanio |
| collection | DOAJ |
| description | ABSTRACT: Objectives: : Antimicrobial resistance, particularly carbapenem resistance, in Gram-negative pathogens poses a significant healthcare threat. Carbapenem resistance rates in Italy are among the highest in Europe. We report the in vitro activity of cefiderocol, a novel siderophore cephalosporin, and comparator antibiotics against Gram-negative isolates from Italy as part of the SIDERO-WT studies. Methods: : Isolates were collected between 2014 and 2018. Minimum inhibitory concentrations (MICs) were determined using International Organization for Standardization and EUCAST guidelines. Antimicrobial susceptibilities were interpreted using EUCAST breakpoints; pharmacodynamic/pharmacokinetic breakpoints were used if EUCAST breakpoints were not specified. Results: : The 2472 isolates [1545 (62.5%) Enterobacterales and 927 (37.5%) non-fermenters] represented a range of infection sources, including nosocomial pneumonia (902; 36.5%), complicated urinary tract infection (374; 15.1%), bloodstream infection (596; 24.1%), complicated intra-abdominal infection (257; 10.4%) and other infection sources (343; 13.9%). Cefiderocol was active against the majority of isolates, regardless of infection source (susceptibility, 94.2−97.3%). A high proportion of non-fermenters (97.6%) and Enterobacterales (95.6%) were cefiderocol-susceptible, although susceptibility was lower in Klebsiella pneumoniae (88.1%). Susceptibility to cefiderocol was significantly (P < 0.01) greater than comparators overall (96.4% vs. 71.3–81.6%) and in non-fermenters (97.6% vs. 44.3–90.3%) across infection sources. Overall 612/2472 isolates (24.8%) were meropenem-resistant (MIC > 8 mg/L), comprising 516/927 (55.7%) non-fermenters and 96/1545 (6.2%) Enterobacterales. Cefiderocol (499/516; 96.7%) activity was greater than colistin (440/516; 85.3%), ceftazidime/avibactam (123/516; 23.8%) and ceftolozane/tazobactam (89/516; 17.2%) in meropenem-resistant non-fermenter isolates. Conclusion: : Susceptibility to cefiderocol was significantly greater than meropenem, colistin, ceftazidime/avibactam and ceftolozane/tazobactam overall, regardless of infection source. |
| first_indexed | 2024-12-22T00:26:54Z |
| format | Article |
| id | doaj.art-b2de32fe727547e9aebc4e4fa7a1c9cb |
| institution | Directory Open Access Journal |
| issn | 2213-7165 |
| language | English |
| last_indexed | 2024-12-22T00:26:54Z |
| publishDate | 2021-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Global Antimicrobial Resistance |
| spelling | doaj.art-b2de32fe727547e9aebc4e4fa7a1c9cb2022-12-21T18:45:02ZengElsevierJournal of Global Antimicrobial Resistance2213-71652021-06-0125390398In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014–2018 studies in ItalyStefano Stracquadanio0Eleonora Torti1Christopher Longshaw2Anne Santerre Henriksen3Stefania Stefani4Department of Biomedical and Biotechnological Sciences, Università di Catania, Via Santa Sofia 97, I-95123 Catania, Italy; Corresponding author.Shionogi Srl, Rome, ItalyInfectious Diseases, Shionogi B.V., London, UKMaxel Consulting ApS, Jyllinge, Denmark; contractor for Shionogi B.V., London, UKDepartment of Biomedical and Biotechnological Sciences, Università di Catania, Via Santa Sofia 97, I-95123 Catania, ItalyABSTRACT: Objectives: : Antimicrobial resistance, particularly carbapenem resistance, in Gram-negative pathogens poses a significant healthcare threat. Carbapenem resistance rates in Italy are among the highest in Europe. We report the in vitro activity of cefiderocol, a novel siderophore cephalosporin, and comparator antibiotics against Gram-negative isolates from Italy as part of the SIDERO-WT studies. Methods: : Isolates were collected between 2014 and 2018. Minimum inhibitory concentrations (MICs) were determined using International Organization for Standardization and EUCAST guidelines. Antimicrobial susceptibilities were interpreted using EUCAST breakpoints; pharmacodynamic/pharmacokinetic breakpoints were used if EUCAST breakpoints were not specified. Results: : The 2472 isolates [1545 (62.5%) Enterobacterales and 927 (37.5%) non-fermenters] represented a range of infection sources, including nosocomial pneumonia (902; 36.5%), complicated urinary tract infection (374; 15.1%), bloodstream infection (596; 24.1%), complicated intra-abdominal infection (257; 10.4%) and other infection sources (343; 13.9%). Cefiderocol was active against the majority of isolates, regardless of infection source (susceptibility, 94.2−97.3%). A high proportion of non-fermenters (97.6%) and Enterobacterales (95.6%) were cefiderocol-susceptible, although susceptibility was lower in Klebsiella pneumoniae (88.1%). Susceptibility to cefiderocol was significantly (P < 0.01) greater than comparators overall (96.4% vs. 71.3–81.6%) and in non-fermenters (97.6% vs. 44.3–90.3%) across infection sources. Overall 612/2472 isolates (24.8%) were meropenem-resistant (MIC > 8 mg/L), comprising 516/927 (55.7%) non-fermenters and 96/1545 (6.2%) Enterobacterales. Cefiderocol (499/516; 96.7%) activity was greater than colistin (440/516; 85.3%), ceftazidime/avibactam (123/516; 23.8%) and ceftolozane/tazobactam (89/516; 17.2%) in meropenem-resistant non-fermenter isolates. Conclusion: : Susceptibility to cefiderocol was significantly greater than meropenem, colistin, ceftazidime/avibactam and ceftolozane/tazobactam overall, regardless of infection source.http://www.sciencedirect.com/science/article/pii/S2213716521001181CefiderocolCarbapenem resistanceGram-negativeAntimicrobial resistance |
| spellingShingle | Stefano Stracquadanio Eleonora Torti Christopher Longshaw Anne Santerre Henriksen Stefania Stefani In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014–2018 studies in Italy Journal of Global Antimicrobial Resistance Cefiderocol Carbapenem resistance Gram-negative Antimicrobial resistance |
| title | In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014–2018 studies in Italy |
| title_full | In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014–2018 studies in Italy |
| title_fullStr | In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014–2018 studies in Italy |
| title_full_unstemmed | In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014–2018 studies in Italy |
| title_short | In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014–2018 studies in Italy |
| title_sort | in vitro activity of cefiderocol and comparators against isolates of gram negative pathogens from a range of infection sources sidero wt 2014 2018 studies in italy |
| topic | Cefiderocol Carbapenem resistance Gram-negative Antimicrobial resistance |
| url | http://www.sciencedirect.com/science/article/pii/S2213716521001181 |
| work_keys_str_mv | AT stefanostracquadanio invitroactivityofcefiderocolandcomparatorsagainstisolatesofgramnegativepathogensfromarangeofinfectionsourcessiderowt20142018studiesinitaly AT eleonoratorti invitroactivityofcefiderocolandcomparatorsagainstisolatesofgramnegativepathogensfromarangeofinfectionsourcessiderowt20142018studiesinitaly AT christopherlongshaw invitroactivityofcefiderocolandcomparatorsagainstisolatesofgramnegativepathogensfromarangeofinfectionsourcessiderowt20142018studiesinitaly AT annesanterrehenriksen invitroactivityofcefiderocolandcomparatorsagainstisolatesofgramnegativepathogensfromarangeofinfectionsourcessiderowt20142018studiesinitaly AT stefaniastefani invitroactivityofcefiderocolandcomparatorsagainstisolatesofgramnegativepathogensfromarangeofinfectionsourcessiderowt20142018studiesinitaly |